Tacão Marta, Tavares Rafael Dos Santos, Teixeira Pedro, Roxo Inês, Ramalheira Elmano, Ferreira Sónia, Henriques Isabel
Emerg Infect Dis. 2017 Aug;23(8):1419-1421. doi: 10.3201/eid2308.170162.
Escherichia coli Ec36 was recovered from a patient in Portugal after treatment with meropenem and colistin. Besides an IncF plasmid with Tn1441d-bla, already reported in clinical strains in this country, E. coli Ec36 co-harbored an IncX4::mcr-1 gene. Results highlight emerging co-resistance to carbapenems and polymyxins after therapy with drugs from both classes.
在使用美罗培南和黏菌素治疗后,从一名葡萄牙患者体内分离出大肠杆菌Ec36。除了该国临床菌株中已报道的携带Tn1441d-bla的IncF质粒外,大肠杆菌Ec36还共同携带一个IncX4::mcr-1基因。结果凸显了在使用这两类药物治疗后出现的对碳青霉烯类和多黏菌素类的共同耐药性。